WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130430
CAS#: N/A
Description: CCL-34 activates the toll-like receptor 4 (TLR4), triggering the maturation of dendritic cells, serving as a potential immunostimulator in the treatment of cancers and other applications.
Hodoodo Cat#: H130430
Name: CCL-34
CAS#: N/A
Chemical Formula: C32H62N2O8
Exact Mass: 602.45
Molecular Weight: 602.850
Elemental Analysis: C, 63.76; H, 10.37; N, 4.65; O, 21.23
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CCL-34; CCL 34
IUPAC/Chemical Name: N-((S)-1-oxo-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1-(undecylamino)propan-2-yl)dodecanamide
InChi Key: RHZGTZCSKQCTKA-JZYYMOCISA-N
InChi Code: InChI=1S/C32H62N2O8/c1-3-5-7-9-11-13-15-17-19-21-27(36)34-25(24-41-32-30(39)29(38)28(37)26(23-35)42-32)31(40)33-22-20-18-16-14-12-10-8-6-4-2/h25-26,28-30,32,35,37-39H,3-24H2,1-2H3,(H,33,40)(H,34,36)/t25-,26+,28-,29-,30+,32-/m0/s1
SMILES Code: CCCCCCCCCCCC(N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(NCCCCCCCCCCC)=O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 602.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Fu SL, Lin CC, Hsu ML, Liu SH, Huang YC, Chen YJ. CCL-34, a synthetic toll- like receptor 4 activator, modulates differentiation and maturation of myeloid dendritic cells. Oncotarget. 2016 Mar 8;7(10):11677-86. doi: 10.18632/oncotarget.7315. PMID: 26883191; PMCID: PMC4905502.
2: Chen F, Zhu J, Wang W. Ulinastatin Attenuates LPS-Induced Inflammation and Inhibits Endoplasmic Reticulum Stress-Induced Apoptosis in Renal Tubular Epithelial Cells via Regulation of the TLR4/NF-κB and Nrf2/HO-1 Pathways. Inflammation. 2021 Dec;44(6):2323-2332. doi: 10.1007/s10753-021-01505-z. Epub 2021 Sep 28. PMID: 34585338.
3: Chou YJ, Lin CC, Dzhagalov I, Chen NJ, Lin CH, Lin CC, Chen ST, Chen KH, Fu SL. Vaccine adjuvant activity of a TLR4-activating synthetic glycolipid by promoting autophagy. Sci Rep. 2020 May 21;10(1):8422. doi: 10.1038/s41598-020-65422-1. PMID: 32439945; PMCID: PMC7242473.
4: Huang LD, Lin HJ, Huang PH, Hsiao WC, Reddy LV, Fu SL, Lin CC. Synthesis of serine-based glycolipids as potential TLR4 activators. Org Biomol Chem. 2011 Apr 7;9(7):2492-504. doi: 10.1039/c0ob00990c. Epub 2011 Feb 21. PMID: 21336404.
5: Hung LC, Lin CC, Hung SK, Wu BC, Jan MD, Liou SH, Fu SL. A synthetic analog of alpha-galactosylceramide induces macrophage activation via the TLR4-signaling pathways. Biochem Pharmacol. 2007 Jun 15;73(12):1957-70. doi: 10.1016/j.bcp.2007.03.006. Epub 2007 Mar 12. PMID: 17445776.
6: Lin YS, Lin CH, Huang LD, Chao T, Kuo CD, Hung LC, Wong FH, Lin CC, Fu SL. The suppression of thoc1 in cancer cell apoptosis mediated by activated macrophages is nitric oxide-dependent. Biochem Pharmacol. 2013 Jul 15;86(2):242-52. doi: 10.1016/j.bcp.2013.05.009. Epub 2013 May 17. PMID: 23688498.
7: Lin YS, Huang LD, Lin CH, Huang PH, Chen YJ, Wong FH, Lin CC, Fu SL. In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. J Biol Chem. 2011 Dec 23;286(51):43782-43792. doi: 10.1074/jbc.M111.285171. Epub 2011 Sep 23. PMID: 21949133; PMCID: PMC3243550.
8: González-Cuesta M, Lai AC, Chi PY, Hsu IL, Liu NT, Wu KC, García Fernández JM, Chang YJ, Ortiz Mellet C. Serine-/Cysteine-Based sp2-Iminoglycolipids as Novel TLR4 Agonists: Evaluation of Their Adjuvancy and Immunotherapeutic Properties in a Murine Model of Asthma. J Med Chem. 2023 Apr 13;66(7):4768-4783. doi: 10.1021/acs.jmedchem.2c01948. Epub 2023 Mar 23. PMID: 36958376; PMCID: PMC10108363.
9: Mrabet D, Laadhar L, Sahli H, Zouari B, Haouet S, Makni S, Sellami S. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int. 2013 Jan;33(1):265-6. doi: 10.1007/s00296-011-2231-1. Epub 2011 Nov 16. PMID: 22083617.
10: Mera-Ramírez A, Castillo A, Orobio Y, Gómez MA, Gallego-Marin C. Screening of TNFα, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. BMC Infect Dis. 2017 Feb 28;17(1):177. doi: 10.1186/s12879-017-2281-4. PMID: 28241747; PMCID: PMC5330139.
11: Atzori C, Bruno A, Agostoni C, Novati S, Gatti S, Scaglia M. Madin Darby canine kidney: a new cell line for Pneumocystis carinii in vitro culture. Parasite. 1996 Jun;3(2):183-5. doi: 10.1051/parasite/1996032183. PMID: 8758555.
